Ipsen SA

Explore Ipsen’s May 2026 governance and buy‑back strategy: how transparent voting rights, modest share repurchase, and employee‑ownership plans aim to boost long‑term value and competitive advantage in biopharma.

Ipsen’s corabotase shows faster onset and higher efficacy than Dysport in Phase II glabellar trials, promising a disruptive entry into the $4.9 bn aesthetic neuromodulator market.

Ipsen’s novel neuroinhibitor, corabotase, shows rapid‑onset, long‑lasting results for upper‑facial lines and may challenge Botox and Dysport in the booming aesthetic market.

IPSEN’s IPN60340 earns FDA Breakthrough Therapy status for AML, delivering 58 % response in patients unsuitable for intensive chemo—plus promising Parkinson’s data from EPITOME.

Ipsen SA has secured regulatory approval in Japan for its rare disease treatment Bylvay, expanding its commercial footprint in a market underserved for progressive familial intrahepatic cholestasis (PFIC) and related cholestatic disorders.

Ipsen SA has reported strong financial results for the first half of 2025, with a 9.8% increase in sales and a raised annual sales outlook.

Ipsen Pharmaceuticals has released its half-year statement for 2025, providing key financial metrics and valuation insights.

Ipsen SA, a French pharmaceutical company, has seen its stock price surge to levels above its 52-week high, driven by strategic share buybacks and a stable financial situation.

Ipsen SA has strengthened its leadership team and pipeline with the appointment of a new Executive Vice President and promising data on its drug IQIRVO, positioning the company for sustained growth and success.

Ipsen SA reported a 11.6% sales growth in Q1 2025, driven by strong performance across all therapeutic areas and contributions from products Iqirvo and Bylvay.